BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schmitz JM, Stotts AL, Rhoades HM, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav 2001;26:167-80. [PMID: 11316375 DOI: 10.1016/s0306-4603(00)00098-8] [Cited by in Crossref: 92] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Sushchyk S, Xi ZX, Wang JB. Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse. J Pharmacol Exp Ther 2016;357:248-57. [PMID: 26903543 DOI: 10.1124/jpet.115.229542] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
2 Carroll KM, Kiluk BD. Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. Psychol Addict Behav 2017;31:847-61. [PMID: 28857574 DOI: 10.1037/adb0000311] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
3 Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, Nunes EV. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007;91:289-92. [PMID: 17681716 DOI: 10.1016/j.drugalcdep.2007.06.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
4 Stotts AL, Mooney ME, Sayre SL, Novy M, Schmitz JM, Grabowski J. Illusory predictors: Generalizability of findings in cocaine treatment retention research. Addict Behav 2007;32:2819-36. [PMID: 17543472 DOI: 10.1016/j.addbeh.2007.04.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
5 Kesner RP, Kirk RA, Clark JK, Moore A, Keefe K. Naloxone injections into CA3 disrupt pattern completion associated with relapse from cocaine seeking. Hippocampus 2016;26:892-8. [PMID: 26815290 DOI: 10.1002/hipo.22570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Winhusen T, Brady KT, Stitzer M, Woody G, Lindblad R, Kropp F, Brigham G, Liu D, Sparenborg S, Sharma G, Vanveldhuisen P, Adinoff B, Somoza E. Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world. Contemp Clin Trials 2012;33:993-1002. [PMID: 22613054 DOI: 10.1016/j.cct.2012.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
7 Chan B, Kondo K, Freeman M, Ayers C, Montgomery J, Kansagara D. Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis. J Gen Intern Med 2019;34:2858-73. [PMID: 31183685 DOI: 10.1007/s11606-019-05074-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
8 Carr MM, Saules KK, Ellis JD, Staples A, Ledgerwood DM, Loverich TM. Development and Validation of the Recognizing Addictive Disorders Scale: A Transdiagnostic Measure of Substance-Related and Other Addictive Disorders. Subst Use Misuse 2020;55:2194-204. [PMID: 32727284 DOI: 10.1080/10826084.2020.1797806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Gowin JL, Ball TM, Wittmann M, Tapert SF, Paulus MP. Individualized relapse prediction: Personality measures and striatal and insular activity during reward-processing robustly predict relapse. Drug Alcohol Depend 2015;152:93-101. [PMID: 25977206 DOI: 10.1016/j.drugalcdep.2015.04.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
10 Lile JA, Stoops WW, Glaser PE, Hays LR, Rush CR. Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance. Drug Alcohol Depend 2011;119:187-93. [PMID: 21737214 DOI: 10.1016/j.drugalcdep.2011.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
11 Nieto MM, Wilson J, Cupo A, Roques BP, Noble F. Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study. J Neurosci 2002;22:1034-41. [PMID: 11826132 [PMID: 11826132 DOI: 10.1523/jneurosci.22-03-01034.2002] [Cited by in Crossref: 51] [Article Influence: 2.6] [Reference Citation Analysis]
12 Frankel PS, Alburges ME, Bush L, Hanson GR, Kish SJ. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 2008;55:41-6. [PMID: 18538358 DOI: 10.1016/j.neuropharm.2008.04.019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health 2013;28:388-406. [PMID: 23731427 DOI: 10.1080/19371918.2013.774673] [Cited by in Crossref: 82] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
14 Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, O'Brien CP. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat 2008;34:378-90. [PMID: 17664051 DOI: 10.1016/j.jsat.2007.05.011] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.1] [Reference Citation Analysis]
15 Bowen S, Witkiewitz K, Clifasefi SL, Grow J, Chawla N, Hsu SH, Carroll HA, Harrop E, Collins SE, Lustyk MK, Larimer ME. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry 2014;71:547-56. [PMID: 24647726 DOI: 10.1001/jamapsychiatry.2013.4546] [Cited by in Crossref: 304] [Cited by in F6Publishing: 230] [Article Influence: 38.0] [Reference Citation Analysis]
16 Mongi-Bragato B, Avalos MP, Guzmán AS, Bollati FA, Cancela LM. Enkephalin as a Pivotal Player in Neuroadaptations Related to Psychostimulant Addiction. Front Psychiatry 2018;9:222. [PMID: 29892236 DOI: 10.3389/fpsyt.2018.00222] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Magill M, Ray LA. Cognitive-behavioral treatment with adult alcohol and illicit drug users: a meta-analysis of randomized controlled trials. J Stud Alcohol Drugs 2009;70:516-27. [PMID: 19515291 DOI: 10.15288/jsad.2009.70.516] [Cited by in Crossref: 307] [Cited by in F6Publishing: 237] [Article Influence: 23.6] [Reference Citation Analysis]
18 Rohsenow DJ. What place does naltrexone have in the treatment of alcoholism? CNS Drugs 2004;18:547-60. [PMID: 15222772 DOI: 10.2165/00023210-200418090-00001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
19 Simmons D, Self DW. Role of mu- and delta-opioid receptors in the nucleus accumbens in cocaine-seeking behavior. Neuropsychopharmacology 2009;34:1946-57. [PMID: 19279569 DOI: 10.1038/npp.2009.28] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
20 Carroll KM, Kosten TR, Rounsaville BJ. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend 2004;75:123-34. [PMID: 15276217 DOI: 10.1016/j.drugalcdep.2004.02.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
21 Giuliano C, Robbins TW, Wille DR, Bullmore ET, Everitt BJ. Attenuation of cocaine and heroin seeking by μ-opioid receptor antagonism. Psychopharmacology (Berl) 2013;227:137-47. [PMID: 23299095 DOI: 10.1007/s00213-012-2949-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
22 Aboujaoude E, Salame WO. Naltrexone: A Pan-Addiction Treatment? CNS Drugs 2016;30:719-33. [PMID: 27401883 DOI: 10.1007/s40263-016-0373-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
23 Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis. JAMA Netw Open 2020;3:e208279. [PMID: 32558914 DOI: 10.1001/jamanetworkopen.2020.8279] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
24 Schmitz JM, Mooney ME, Moeller FG, Stotts AL, Green C, Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend 2008;94:142-50. [PMID: 18164144 DOI: 10.1016/j.drugalcdep.2007.11.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
25 Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, Wood E, Fairbairn N. Treatment of stimulant use disorder: A systematic review of reviews. PLoS One 2020;15:e0234809. [PMID: 32555667 DOI: 10.1371/journal.pone.0234809] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
26 Lin SK. Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature. Br J Clin Pharmacol 2014;77:242-52. [PMID: 23701272 DOI: 10.1111/bcp.12163] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
27 Tasić JK, Valkanou MK, Đukanović B, Banković D, Janjić V. Relapse Risk Factors in Heroin Addicts Treated with Naltrexone and Naltrexone-Behavioural Psychotherapy. Int J Ment Health Addiction 2018;16:351-65. [DOI: 10.1007/s11469-017-9782-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
28 Savulich G, Riccelli R, Passamonti L, Correia M, Deakin JF, Elliott R, Flechais RS, Lingford-Hughes AR, McGonigle J, Murphy A, Nutt DJ, Orban C, Paterson LM, Reed LJ, Smith DG, Suckling J, Tait R, Taylor EM, Sahakian BJ, Robbins TW, Ersche KD. Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery. Transl Psychiatry 2017;7:e1054. [PMID: 28267152 DOI: 10.1038/tp.2017.34] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
29 Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, Grabowski J. Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2009;101:34-41. [PMID: 19058926 DOI: 10.1016/j.drugalcdep.2008.10.016] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 6.1] [Reference Citation Analysis]
30 Bowen S, Chawla N, Collins SE, Witkiewitz K, Hsu S, Grow J, Clifasefi S, Garner M, Douglass A, Larimer ME, Marlatt A. Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abus 2009;30:295-305. [PMID: 19904665 DOI: 10.1080/08897070903250084] [Cited by in Crossref: 350] [Cited by in F6Publishing: 290] [Article Influence: 29.2] [Reference Citation Analysis]
31 Schroeder JA, Hummel M, Simpson AD, Sheikh R, Soderman AR, Unterwald EM. A role for mu opioid receptors in cocaine-induced activity, sensitization, and reward in the rat. Psychopharmacology (Berl) 2007;195:265-72. [PMID: 17687547 DOI: 10.1007/s00213-007-0883-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
32 Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller FG. High-dose naltrexone therapy for cocaine-alcohol dependence. Am J Addict 2009;18:356-62. [PMID: 19874153 DOI: 10.3109/10550490903077929] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
33 Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology 2013;38:2427-38. [PMID: 23736314 DOI: 10.1038/npp.2013.143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
34 Sánchez E, Villanueva R, Santonja F, Rubio M. Predicting cocaine consumption in Spain: A mathematical modelling approach. Drugs: Education, Prevention and Policy 2010;18:108-15. [DOI: 10.3109/09687630903443299] [Cited by in Crossref: 10] [Article Influence: 0.8] [Reference Citation Analysis]
35 Epstein DH, Preston KL. The reinstatement model and relapse prevention: a clinical perspective. Psychopharmacology (Berl) 2003;168:31-41. [PMID: 12721778 DOI: 10.1007/s00213-003-1470-6] [Cited by in Crossref: 93] [Cited by in F6Publishing: 93] [Article Influence: 4.9] [Reference Citation Analysis]
36 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
37 Schmitz JM, Green CE, Stotts AL, Lindsay JA, Rathnayaka NS, Grabowski J, Moeller FG. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone. Drug Alcohol Depend 2014;136:100-7. [PMID: 24424425 DOI: 10.1016/j.drugalcdep.2013.12.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
38 Czoty PW, Stoops WW, Rush CR. Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research. Pharmacol Rev 2016;68:533-62. [PMID: 27255266 DOI: 10.1124/pr.115.011668] [Cited by in Crossref: 80] [Cited by in F6Publishing: 79] [Article Influence: 16.0] [Reference Citation Analysis]
39 Schmitz JM, Rathnayaka N, Green CE, Moeller FG, Dougherty AE, Grabowski J. Combination of Modafinil and d-amphetamine for the Treatment of Cocaine Dependence: A Preliminary Investigation. Front Psychiatry 2012;3:77. [PMID: 22969732 DOI: 10.3389/fpsyt.2012.00077] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
40 Stotts AL, Green C, Masuda A, Grabowski J, Wilson K, Northrup TF, Moeller FG, Schmitz JM. A stage I pilot study of acceptance and commitment therapy for methadone detoxification. Drug Alcohol Depend 2012;125:215-22. [PMID: 22425411 DOI: 10.1016/j.drugalcdep.2012.02.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
41 Moore CF, Schlain GS, Mancino S, Sabino V, Cottone P. A behavioral and pharmacological characterization of palatable diet alternation in mice. Pharmacol Biochem Behav 2017;163:1-8. [PMID: 29097161 DOI: 10.1016/j.pbb.2017.10.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
42 Mooney ME, Schmitz JM, Moeller FG, Grabowski J. Safety, tolerability and efficacy of levodopa-carbidopa treatment for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007;88:214-23. [PMID: 17134849 DOI: 10.1016/j.drugalcdep.2006.10.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
43 Mooney ME, Herin DV, Specker S, Babb D, Levin FR, Grabowski J. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2015;153:94-103. [PMID: 26116930 DOI: 10.1016/j.drugalcdep.2015.05.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
44 Schmitz JM, Mooney ME, Green CE, Lane SD, Steinberg JL, Swann AC, Moeller FG. Baseline neurocognitive profiles differentiate abstainers and non-abstainers in a cocaine clinical trial. J Addict Dis 2009;28:250-7. [PMID: 20155594 DOI: 10.1080/10550880903028502] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]